2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $342M | $479M | $345M | $227M | $190M |
Cost of Revenue | $279M | $378M | $315M | $189M | $158M |
Gross Profit | $64M | $101M | $29M | $38M | $32M |
Gross Profit % | 19% | 21% | 8.5% | 17% | 17% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | -$7.3M | $13M | -$285M | -$65M | -$67M |
Dep. & Amort. | $6.8M | $15M | $42M | $32M | $31M |
Def. Tax | $52K | -$21M | -$9.3M | $2K | $0 |
Stock Comp. | $8.9M | $5M | $8.4M | $5.1M | $2.4M |
Chg. in WC | -$44M | -$63M | $40M | $12M | $9.7M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $75M | $27M | $21M | $30M | $26M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $75M | $27M | $21M | $30M | $26M |
Receivables | $25M | $42M | $17M | $17M | $15M |
Inventory | $89M | $189M | $111M | $75M | $51M |
HYFM reported a challenging 2024, with net sales declining 20.9% year-over-year in Q4 due to oversupply in the cannabis industry and weaker proprietary brand performance.
The company plans to focus on improving its proprietary brand mix, targeting a higher margin mix for 2025, and expects adjusted EBITDA to remain negative but improve compared to 2024.
Cost-saving initiatives, including facility consolidations and SG&A reductions, have been successful, with further savings of $2-3 million anticipated in 2025.
HYFM is diversifying revenue streams by increasing sales outside the U.S. and Canada and expanding into non-cannabis markets, with new product launches planned for 2025.
The company is exploring strategic alternatives, including potential acquisitions, divestitures, or combinations, to enhance shareholder value and strengthen its position in the industry.